WallStSmart

Burning Rock Biotech Ltd (BNR)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 8907% more annual revenue ($46.34B vs $514.43M). TMO leads profitability with a 15.0% profit margin vs -11.5%. TMO earns a higher WallStSmart Score of 60/100 (C+).

BNR

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: -4.98

TMO

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BNR.

TMOSignificantly Overvalued (-76.7%)

Margin of Safety

-76.7%

Fair Value

$345.06

Current Price

$609.82

$264.76 premium

UndervaluedFair: $345.06Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNR2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

TMO2 strengths · Avg: 9.0/10
Market CapQuality
$225.48B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

BNR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$129.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-10.7%2/10

ROE of -10.7% — below average capital efficiency

Revenue GrowthGrowth
-18.9%2/10

Revenue declined 18.9%

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.804/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BNR

The strongest argument for BNR centers on Debt/Equity, Price/Book.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : BNR

The primary concerns for BNR are EPS Growth, Market Cap, Return on Equity.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BNR profiles as a turnaround stock while TMO is a value play — different risk/reward profiles.

BNR carries more volatility with a beta of 1.39 — expect wider price swings.

TMO is growing revenue faster at 10.5% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (60/100 vs 31/100) and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Burning Rock Biotech Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · China

Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?